MaaT Pharma reinforces its team with David Salako, a seasoned oncology therapeutic development director
(Lyon, February 16th, 2017) – As MaaT Pharma is growing and its clinical activities are expanding, the biotech ramps up its clinical team with David Salako as its new oncology therapeutic development director. On one hand, David Salako will oversee ongoing and upcoming clinical trials in the fields of hematological oncology (2 clinical trials on Acute Myeloid Leukemia are currently taking place) with 15+ years clinical development experience. On the other hand, Corentin Le Camus, who joined MaaT as Therapeutic Development Director, will lead the clinical trials in patients Bone and Joint infections (Osiris study).
A further step forward for the biotech that focuses on microbiota-centric solutions to treat gut imbalance due to high-dose antibiotics or chemotherapies.
Commenting on his appointment, David Salako said: “I am pleased to join the company at such important time. MaaT Pharma’s revolutionary and rapid approach plays a considerable part in the evolution of individualized treatment therapies. It is thrilling to be part of this adventure”.
“David’s experience in oncology alongside Corentin’s background in Joint and Bone infection is a real asset to strengthen and establish our expertise in these fields” added Hervé Affagard, CEO and co-founder of MaaT Pharma.
With a deep knowledge of the biopharmaceutical industry and a strong background in international clinical development, David Salako was most recently in charge of clinical trials at Erytech Pharma, a Euronext company, and International Clinical Project Officer at MDS Pharma (Inc. reseach).
David holds a Master Degree in biological and medical engineering and a MBA from IAE Paris Sorbonne. He also graduated from Claude Bernard Lyon I and Paris Descartes Universities with a European degree in market Access.
About MaaT Pharma
Founded at the end of 2014 and based in Lyon (France), MaaT Pharma (Microbiota as a Therapy) is a microbiome–based biotech company revolutionizing and shaping individualized therapies to treat serious diseases linked to dysbiosis (gut microbiota imbalances). MaaT Pharma is currently developing its first candidate using its proprietary Autologous Fecal Microbiota Transfer Platform for patients suffering from leukemia, bone and joint infections, as these harsh treatments provoke dysbiosis. MaaT Pharma’s revolutionary and rapid approach plays a considerable part in the evolution of individualized treatment therapies.
Pauline Richaud, TBWA\CORPORATE
Email : firstname.lastname@example.org
Phone: +33 (0) 6 45 68 42 72